{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:49Z","timestamp":1786998409028,"version":"build-2736575974"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["19\/190"],"award-info":[{"award-number":["19\/190"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["102539"],"award-info":[{"award-number":["102539"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001516","name":"National Heart Foundation of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000971","name":"Diabetes Australia","doi-asserted-by":"publisher","award":["Y19G-BBER"],"award-info":[{"award-number":["Y19G-BBER"]}],"id":[{"id":"10.13039\/501100000971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.yjmcc.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T17:49:41Z","timestamp":1745171381000},"page":"76-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["New insights into diabetes-induced cardiac pathology"],"prefix":"10.1016","volume":"203","author":[{"given":"K.L.","family":"Weeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.D.","family":"Delbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yjmcc.2025.04.008_bb0005","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0010","first-page":"8","article-title":"The heart\u2019s performance: when diabetes is the puppeteer","author":"Delbridge","year":"2020","journal-title":"Diabetes Management Journal Nov Edn."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0015","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1111\/dom.14830","article-title":"Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: a 21st century assessment","volume":"24","author":"Aroda","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0020","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.hrthm.2024.05.063","article-title":"Sudden cardiac death due to ventricular arrhythmia in diabetes mellitus: a bench to bedside review","volume":"21","author":"Chakraborty","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0025","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/ATVBAHA.114.303090","article-title":"Diabetes mellitus and ischemic diseases","volume":"34","author":"Howangyin","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0030","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/hrt.2005.067231","article-title":"Diabetic heart disease","volume":"84","author":"Marwick","year":"2008","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2337\/dbi23-0019","article-title":"Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology","volume":"73","author":"Heather","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0040","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1463-1326.2007.00803.x","article-title":"Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes","volume":"10","author":"Brooks","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0002-9149(99)00774-2","article-title":"Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus","volume":"85","author":"Poirier","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0050","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/biomedicines12092031","article-title":"Subclinical left ventricular dysfunction over seven-year follow-up in type 2 diabetes patients without cardiovascular diseases","volume":"12","author":"Akasheva","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0055","doi-asserted-by":"crossref","first-page":"H584","DOI":"10.1152\/ajpheart.00334.2023","article-title":"The cardiomyocyte origins of diastolic dysfunction: cellular components of myocardial \u201cstiffness,\u201d","volume":"326","author":"Janssens","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension","volume":"117","author":"van Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0065","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2011.1201","article-title":"Progression of left ventricular diastolic dysfunction and the risk of heart failure","volume":"306","author":"Kane","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yjmcc.2022.09.005","article-title":"HFpEF etiology - can focus on sex-specific mechanisms deliver insights for all?","volume":"173","author":"Delbridge","year":"2022","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0075","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0080","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: a systematic review and meta-analysis","author":"Waqas","year":"2025","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0090","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0095","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.bbadis.2017.10.035","article-title":"Molecular mechanisms of cardiac pathology in diabetes - experimental insights","volume":"1864","author":"Varma","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways","volume":"142","author":"Huynh","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0105","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/CIRCRESAHA.119.316260","article-title":"Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized 13C MRI","volume":"126","author":"Rider","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0110","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/01.CIR.0000127959.28627.F8","article-title":"Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women","volume":"109","author":"Peterson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12350-011-9362-3","article-title":"Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance","volume":"18","author":"McGill","year":"2011","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0120","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2008.07.062","article-title":"Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus","volume":"52","author":"Rijzewijk","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0125","doi-asserted-by":"crossref","first-page":"E578","DOI":"10.1152\/ajpendo.00093.2009","article-title":"The Randle cycle revisited: a new head for an old hat","volume":"297","author":"Hue","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI5001","article-title":"Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity","volume":"103","author":"Dresner","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0135","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/CIRCULATIONAHA.119.043319","article-title":"Increasing fatty acid oxidation prevents high-fat diet-induced cardiomyopathy through regulating Parkin-mediated Mitophagy","volume":"142","author":"Shao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yjmcc.2024.02.009","article-title":"Myocardial glycophagy flux dysregulation and glycogen accumulation characterize diabetic cardiomyopathy","volume":"189","author":"Mellor","year":"2024","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lfs.2014.03.020","article-title":"Glucose as an agent of post-translational modification in diabetes--New cardiac epigenetic insights","volume":"129","author":"Mellor","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/1440-1681.12370","article-title":"Myocardial glycogen dynamics: new perspectives on disease mechanisms","volume":"42","author":"Chandramouli","year":"2015","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41387-021-00150-7","article-title":"Elevated myocardial fructose and sorbitol levels are associated with diastolic dysfunction in diabetic patients, and cardiomyocyte lipid inclusions in vitro","volume":"11","author":"Daniels","year":"2021","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0160","doi-asserted-by":"crossref","first-page":"H751","DOI":"10.1152\/ajpheart.00260.2021","article-title":"Why the diabetic heart is energy inefficient: a ketogenesis and ketolysis perspective","volume":"321","author":"Mishra","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.metabol.2017.08.005","article-title":"The diabetic heart utilizes ketone bodies as an energy source","volume":"77","author":"Mizuno","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0170","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1161\/CIRCRESAHA.123.321872","article-title":"Ketones and the heart: metabolic principles and therapeutic implications","volume":"132","author":"Matsuura","year":"2023","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0175","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-021-01245-2","article-title":"MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics","volume":"20","author":"Jakubik","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.hlc.2011.11.002","article-title":"A microRNA guide for clinicians and basic scientists: background and experimental techniques","volume":"21","author":"Bernardo","year":"2012","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0190","doi-asserted-by":"crossref","first-page":"1124613","DOI":"10.3389\/fendo.2023.1124613","article-title":"Diabetic cardiomyopathy: the role of microRNAs and long non-coding RNAs","volume":"14","author":"Macvanin","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12933-024-02252-9","article-title":"Roles of non-coding RNA in diabetic cardiomyopathy","volume":"23","author":"Yao","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.321","article-title":"lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy","volume":"8","author":"Zhou","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0205","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s41419-018-1029-4","article-title":"Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy","volume":"9","author":"Yang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174915","article-title":"CircRNA CDR1as promotes cardiomyocyte apoptosis through activating hippo signaling pathway in diabetic cardiomyopathy","volume":"922","author":"Shao","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0215","article-title":"The interaction between non-coding RNAs and SGLT2: a review","author":"Jarosz-Popek","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0220","first-page":"6346","article-title":"A study of the effects of SGLT-2 inhibitors on diabetic cardiomyopathy through miR-30d\/KLF9\/VEGFA pathway","volume":"24","author":"Zhang","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0225","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/j.2040-4603.2019.tb00071.x","article-title":"Impact of estrogens on the regulation of white, beige, and brown adipose tissue depots","volume":"9","author":"Bernasochi","year":"2019","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0230","first-page":"416","article-title":"Epicardial adipose tissue: far more than a fat depot","volume":"4","author":"Talman","year":"2014","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0235","article-title":"Inflammation and cardiovascular diseases in the elderly: the role of Epicardial adipose tissue","volume":"9","author":"Conte","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0240","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0002-9149(99)80116-7","article-title":"Quantitative measurement of normal and excessive (cor adiposum) subepicardial adipose tissue, its clinical significance, and its effect on electrocardiographic QRS voltage","volume":"76","author":"Shirani","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0245","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ahj.2007.03.019","article-title":"Human epicardial adipose tissue: a review","volume":"153","author":"Sacks","year":"2007","journal-title":"Am. Heart J."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2015.04.058","article-title":"Electrophysiological, Electroanatomical, and structural remodeling of the Atria as consequences of sustained obesity","volume":"66","author":"Mahajan","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0255","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jacc.2020.07.017","article-title":"Epicardial adipose tissue accumulation confers atrial conduction abnormality","volume":"76","author":"Nalliah","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0260","doi-asserted-by":"crossref","first-page":"1154824","DOI":"10.3389\/fendo.2023.1154824","article-title":"Epicardial adipocytes in the pathogenesis of atrial fibrillation: an update on basic and translational studies","volume":"14","author":"Willar","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0265","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/eurheartj\/eht099","article-title":"Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines","volume":"36","author":"Venteclef","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0270","doi-asserted-by":"crossref","first-page":"E164","DOI":"10.1152\/ajpendo.00374.2019","article-title":"Acute interaction between human epicardial adipose tissue and human atrial myocardium induces arrhythmic susceptibility","volume":"318","author":"Babakr","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/cvr\/cvv208","article-title":"Human epicardial adipose tissue has a specific transcriptomic signature depending on its anatomical peri-atrial, peri-ventricular, or peri-coronary location","volume":"108","author":"Gaborit","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.990155","article-title":"Fat-to-heart crosstalk in health and disease","volume":"14","author":"Lodewijks","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0285","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0735-1097(01)01710-7","article-title":"Relative expression of immunolocalized connexins 40 and 43 correlates with human atrial conduction properties","volume":"39","author":"Kanagaratnam","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0290","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12933-015-0173-8","article-title":"Targeting metabolic disturbance in the diabetic heart","volume":"14","author":"Fuentes-Antr\u00e1s","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0300","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1152\/physrev.00011.2023","article-title":"CD36 as a gatekeeper of myocardial lipid metabolism and therapeutic target for metabolic disease","volume":"104","author":"Glatz","year":"2024","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0305","doi-asserted-by":"crossref","first-page":"H976","DOI":"10.1152\/ajpheart.00088.2002","article-title":"Echocardiographic assessment of cardiac function in diabetic db\/db and transgenic db\/db-hGLUT4 mice","volume":"283","author":"Semeniuk","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0310","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.RES.0000165478.06813.58","article-title":"Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart","volume":"96","author":"Hu","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0315","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/cvr\/cvab043","article-title":"Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart","volume":"118","author":"Prakoso","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0320","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2337\/db14-1560","article-title":"Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study","volume":"64","author":"Le Page","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0325","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diabetes.50.6.1414","article-title":"IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress","volume":"50","author":"Kajstura","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0330","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.RES.0000264104.25265.b6","article-title":"Deficiency Rescues Lipotoxic Cardiomyopathy |","volume":"100","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0335","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1128\/MCB.00133-14","article-title":"Deficiency of a lipid droplet protein, Perilipin 5, suppresses myocardial lipid accumulation, thereby preventing type 1 diabetes-induced heart malfunction","volume":"34","author":"Kuramoto","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0340","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/ijo.2013.103","article-title":"Cardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesity","volume":"38","year":"2014","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0345","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jtcvs.2015.08.083","article-title":"Surgical resection of circumferential epicardial adipose tissue hypertrophy: case report and systematic review of the literature","volume":"151","author":"Smail","year":"2016","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0350","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1749-8090-9-2","article-title":"Epicardial adipose excision slows the progression of porcine coronary atherosclerosis","volume":"9","author":"McKenney","year":"2014","journal-title":"J. Cardiothorac. Surg."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0355","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.omtn.2022.07.007","article-title":"Therapeutic knockdown of miR-320 improves deteriorated cardiac function in a pre-clinical model of non-ischemic diabetic heart disease","volume":"29","author":"Ghosh","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0360","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.7150\/thno.99507","article-title":"Cardiomyocyte-derived small extracellular vesicle: a new mechanism driving diabetic cardiac fibrosis and cardiomyopathy","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0365","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/cells11193117","article-title":"In vivo inhibition of miR-34a modestly limits cardiac enlargement and fibrosis in a mouse model with established type 1 diabetes-induced cardiomyopathy, but does not improve diastolic function","volume":"11","author":"Bernardo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0370","first-page":"1771","article-title":"miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart, future","volume":"7","author":"Bernardo","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0375","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/15476286.2016.1181251","article-title":"Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: implications for treating cardiac pathology and other diseases","volume":"14","author":"Ooi","year":"2017","journal-title":"RNA Biol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0380","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.omtn.2021.04.018","article-title":"Improved cardiac-specific delivery of RAGE siRNA within small extracellular vesicles engineered to express intense cardiac targeting peptide attenuates myocarditis","volume":"24","author":"Kim","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114836","article-title":"Targeting non-coding RNAs in sEVs: the biological functions and potential therapeutic strategy of diabetic cardiomyopathy","volume":"163","author":"Ding","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12371","article-title":"Engineered small extracellular vesicle-mediated NOX4 siRNA delivery for targeted therapy of cardiac hypertrophy","volume":"12","author":"Kang","year":"2023","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0395","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.omtn.2023.04.025","article-title":"LncRNA ZNF593-AS alleviates diabetic cardiomyopathy via suppressing IRF3 signaling pathway","volume":"32","author":"Xie","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0400","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13062-022-00346-6","article-title":"LncRNA Airn alleviates diabetic cardiac fibrosis by inhibiting activation of cardiac fibroblasts via a m6A-IMP2-p53 axis","volume":"17","author":"Peng","year":"2022","journal-title":"Biol. Direct"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0405","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.7150\/thno.31052","article-title":"LncRNA DCRF regulates cardiomyocyte autophagy by targeting miR-551b-5p in diabetic cardiomyopathy","volume":"9","author":"Feng","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0410","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00011-021-01500-y","article-title":"NORAD lentivirus shRNA mitigates fibrosis and inflammatory responses in diabetic cardiomyopathy via the ceRNA network of NORAD\/miR-125a-3p\/Fyn","volume":"70","author":"Liu","year":"2021","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0415","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1042\/CS20210052","article-title":"Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy - current and future perspectives","volume":"135","author":"Prakoso","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0420","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.hlc.2018.03.005","article-title":"Adeno-associated virus gene therapy: translational progress and future prospects in the treatment of heart failure","volume":"27","author":"Bass-Stringer","year":"2018","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0425","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0430","doi-asserted-by":"crossref","first-page":"H840","DOI":"10.1152\/ajpheart.00632.2019","article-title":"Gene therapy targeting cardiac phosphoinositide 3-kinase (p110\u03b1) attenuates cardiac remodeling in type 2 diabetes","volume":"318","author":"Prakoso","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0435","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1042\/CS20170063","article-title":"Phosphoinositide 3-kinase (p110\u03b1) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction","volume":"131","author":"Prakoso","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.719290","article-title":"Bone morphogenetic protein 7 gene delivery improves cardiac structure and function in a murine model of diabetic cardiomyopathy","volume":"12","author":"Tate","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0445","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166713","article-title":"Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0450","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00109-023-02397-2","article-title":"A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology","volume":"102","author":"Weeks","year":"2024","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0455","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.hlc.2024.11.021","article-title":"AAVs as gene delivery tools for diabetic heart disease and failure: key considerations for clinicians and preclinical researchers","volume":"34","author":"Weeks","year":"2025","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101277","article-title":"Cardiac gene delivery using ultrasound: state of the field","volume":"32","author":"Singh","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113998","article-title":"Ultrasonic particles: an approach for targeted gene delivery","volume":"179","author":"Walsh","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0470","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jconrel.2022.01.027","article-title":"Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles","volume":"343","author":"Evers","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0475","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","article-title":"Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy","volume":"372","author":"Soroudi","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0480","article-title":"Effects of treatment with methotrexate associated to lipid nanoparticles on diabetic cardiomyopathy in rats","volume":"263","author":"Maranhao","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yjmcc.2025.04.008_bb0485","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.3301","article-title":"Effective cardiac mRNA delivery using lipid nanoparticles","volume":"44","author":"Labonia","year":"2023","journal-title":"Eur. Heart J."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282825000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282825000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:09:48Z","timestamp":1778040588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282825000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":97,"alternative-id":["S0022282825000665"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2025.04.008","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into diabetes-induced cardiac pathology","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}